Breaking News Instant updates and real-time market news.

FIT

Fitbit

$3.75

0.305 (8.85%)

12:00
10/16/19
10/16
12:00
10/16/19
12:00

Fitbit rises 8.7%

Fitbit is up 8.7%, or 30c to $3.75.

FIT Fitbit
$3.75

0.305 (8.85%)

08/01/19
SBSH
08/01/19
NO CHANGE
Target $2
SBSH
Sell
Fitbit price target lowered to $2 from $5 at Citi
Citi analyst Jim Suva lowered his price target for Fitbit to $2 from $5 saying the Q3 guidance miss "on all metrics" overshadowed the company's Q2 results. Fitbit's current tangible book value is $2.13, contends the analyst, who projects the tangible book value to be $2.02 in a year from now. His main concern with Fitbit continues to be that the company lacks a mass appeal smartwatch with full two-way texting functionality, such as the Apple Watch. He keeps a Sell rating on the shares.
08/28/19
CHLM
08/28/19
NO CHANGE
Target $7
CHLM
Buy
Craig-Hallum reiterates Buy on Fitbit after paid subscription service news
Fitbit's paid subscription service announced this morning leverages the company's user data into actionable guidance and coaching aimed at improving movement, sleep, and diet, Craig-Hallum analyst Alex Fuhrman tells investors in a research note. The company's the healthcare opportunities discussed for years potentially represent a path towards a return to consistent revenue growth and profitability, adds the analyst. He continues to believe Fitbit is in the midst of a "significant evolution" in strategy and reiterates a Buy rating on the shares with a $7 price target.
09/24/19
DADA
09/24/19
NO CHANGE
Target $5.75
DADA
Buy
Fitbit overall business much healthier than it appears, says DA Davidson
DA Davidson analyst Tom Forte kept his Buy rating and $5.75 price target on Fitbit, saying that a potential sale of the company as speculated by Reuters on Friday would unlock "significant shareholder value" and also allow it to operate without the scrutiny while it pivots to its "large" healthcare-related opportunity. The analyst notes that the stock has declined since its Q2 results and disappointing guidance in late July, but believes that the smartwatch sales decline of 27% in the quarter was driven by "one disappointing device". Forte adds that although Fitbit's smartwatch sales are contracting, the company's overall device sales grew 30.4%, which he sees as a "sign that the overall business is much healthier than reflected in its current share price."
09/25/19
WBLR
09/25/19
NO CHANGE
WBLR
Market Perform
Timing 'imperfect' for Fitbit to pursue sale, sayst William Blair
The timing is "imperfect" for Fitbit to pursue a sale in the near future and management should be able to make the case to let its current strategy play out further, William Blair analyst Jeffrey Garro tells investors in a research note. Last Friday, various media reports broke the news that Fitbit has hired an investment bank, Qatalyst Partners, to explore a sale, the analyst points out. The company has a large, growing, and loyal active user base and has made positive strides in proving itself as a health and wellness differentiator, says Garro. However, the analyst does not have enough confidence that the board will find a right match for its valuation expectations, "if it gets that far in the near term." He sees the stock's risk/reward as balanced and keeps a Market Perform rating on Fitbit.

TODAY'S FREE FLY STORIES

SNCR

Synchronoss

$4.01

-0.26 (-6.09%)

, T

AT&T

$39.37

(0.00%)

08:16
11/12/19
11/12
08:16
11/12/19
08:16
Hot Stocks
Synchronoss collaborates with CCMI joint venture »

Synchronoss Technologies…

SNCR

Synchronoss

$4.01

-0.26 (-6.09%)

T

AT&T

$39.37

(0.00%)

S

Sprint

$5.91

-0.2 (-3.27%)

TMUS

T-Mobile

$79.64

-1.28 (-1.58%)

VZ

Verizon

$59.61

0.27 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 29

    Jan

  • 30

    Jan

GILD

Gilead

$64.66

-0.68 (-1.04%)

08:15
11/12/19
11/12
08:15
11/12/19
08:15
Initiation
Gilead initiated  »

Gilead initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AFG

American Financial Group

$109.84

-0.75 (-0.68%)

08:14
11/12/19
11/12
08:14
11/12/19
08:14
Conference/Events
American Financial Group management to meet with Sandler ONeill »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

SCPH

scPharmaceuticals

$5.26

0.11 (2.14%)

08:13
11/12/19
11/12
08:13
11/12/19
08:13
Hot Stocks
scPharmaceuticals expects 2019 cash, cash equivalents $65M-$70M »

Based on its current…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCPH

scPharmaceuticals

$5.26

0.11 (2.14%)

08:12
11/12/19
11/12
08:12
11/12/19
08:12
Earnings
scPharmaceuticals reports Q3 EPS (31c), consensus (45c) »

"We continue to make…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$16.90

-0.58 (-3.32%)

08:12
11/12/19
11/12
08:12
11/12/19
08:12
Hot Stocks
Amarin jumps as FDA posts documents for Vascepa advisory committee meeting »

Shares of Amarin (AMRN)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 28

    Dec

CBMG

Cellular Biomedicine

$17.86

0.11 (0.62%)

08:12
11/12/19
11/12
08:12
11/12/19
08:12
Downgrade
Cellular Biomedicine rating change  »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VCNX

Vaccinex

$5.05

0.19 (3.91%)

08:11
11/12/19
11/12
08:11
11/12/19
08:11
Earnings
Vaccinex reports Q3 revenue $404,000, consensus 30,000 »

"The highlight of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RKDA

Arcadia Biosciences

$4.08

-0.015 (-0.37%)

, BIOX

Bioceres

$5.70

-0.2 (-3.39%)

08:11
11/12/19
11/12
08:11
11/12/19
08:11
Hot Stocks
Verdeca receives approval of HB4 drought and herbicide tolerant soybeans »

Verdeca, a joint venture…

RKDA

Arcadia Biosciences

$4.08

-0.015 (-0.37%)

BIOX

Bioceres

$5.70

-0.2 (-3.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NH

NantHealth

$0.70

0.008 (1.16%)

08:11
11/12/19
11/12
08:11
11/12/19
08:11
Hot Stocks
NantHealth reports FDA marketing authorization of Omics Core »

NantHealth reported FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$16.90

-0.58 (-3.32%)

08:11
11/12/19
11/12
08:11
11/12/19
08:11
Hot Stocks
Amarin soars after FDA posts briefing docs ahead of Nov. 14 panel »

Shares of Amarin are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 28

    Dec

SWTX

SpringsWorks Therapeutics

$18.42

-0.1 (-0.54%)

08:10
11/12/19
11/12
08:10
11/12/19
08:10
Earnings
SpringsWorks Therapeutics reports Q3 EPS ($1.77), consensus (47c) »

"The third quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLNE

Clean Energy

$2.23

-0.01 (-0.45%)

08:09
11/12/19
11/12
08:09
11/12/19
08:09
Earnings
Clean Energy reports Q3 EPS (2c), consensus (2c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

HON

Honeywell

$180.73

-0.48 (-0.26%)

08:09
11/12/19
11/12
08:09
11/12/19
08:09
Hot Stocks
Honeywell Process Solutions selected by Kuwait Integrated Petroleum Industries »

Honeywell announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLRB

Cellectar Biosciences

$1.30

-0.095 (-6.81%)

08:09
11/12/19
11/12
08:09
11/12/19
08:09
Hot Stocks
Cellectar Biosciences expects cash to fund operations into 1Q21 »

As of September 30, 2019,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLRB

Cellectar Biosciences

$1.30

-0.095 (-6.81%)

08:08
11/12/19
11/12
08:08
11/12/19
08:08
Earnings
Cellectar Biosciences reports Q3 EPS (42c), consensus (38c) »

"We continue to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBRX

Moleculin Biotech

$1.05

-0.02 (-1.87%)

08:08
11/12/19
11/12
08:08
11/12/19
08:08
Hot Stocks
Moleculin Biotech receives FDA approval for IND of WP1066 »

Moleculin Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

LOGC

LogicBio Therapeutics

$9.49

0.09 (0.96%)

08:07
11/12/19
11/12
08:07
11/12/19
08:07
Hot Stocks
LogicBio Therapeutics expects cash to fund operations into 2021 »

Cash, cash equivalents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGC

LogicBio Therapeutics

$9.49

0.09 (0.96%)

08:07
11/12/19
11/12
08:07
11/12/19
08:07
Earnings
LogicBio Therapeutics reports Q3 EPS (48c), consensus (46c) »

"This has been a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$16.90

-0.58 (-3.32%)

08:06
11/12/19
11/12
08:06
11/12/19
08:06
Hot Stocks
Breaking Hot Stocks news story on Amarin »

Amarin jumps 7% to $18.13…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 28

    Dec

MPAA

Motorcar Parts

$19.96

-0.66 (-3.20%)

08:06
11/12/19
11/12
08:06
11/12/19
08:06
Earnings
Motorcar Parts reports Q2 adj. EPS 68c, consensus 41c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

FATE

Fate Therapeutics

$14.49

-0.09 (-0.62%)

08:06
11/12/19
11/12
08:06
11/12/19
08:06
Initiation
Fate Therapeutics initiated  »

Fate Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LM

Legg Mason

$38.33

0.17 (0.45%)

08:06
11/12/19
11/12
08:06
11/12/19
08:06
Hot Stocks
Legg Mason reports AUM of $791.0B as of October 31 »

Legg Mason reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$39.21

1.09 (2.86%)

, VIA

Viacom

$26.40

0.87 (3.41%)

08:06
11/12/19
11/12
08:06
11/12/19
08:06
Hot Stocks
CBS, Viacom merger expected to close in early December »

On August 13, CBS (CBS)…

CBS

CBS

$39.21

1.09 (2.86%)

VIA

Viacom

$26.40

0.87 (3.41%)

VIAB

Viacom

$23.46

0.71 (3.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 14

    Nov

  • 14

    Nov

  • 09

    Dec

08:05
11/12/19
11/12
08:05
11/12/19
08:05
Conference/Events
Craig-Hallum to hold a conference »

10th Annual Craig-Hallum…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.